Tetracycline topical Pregnancy and Breastfeeding Warnings
Brand names: Topicycline
Tetracycline topical Pregnancy Warnings
Tetracycline topical has been assigned to pregnancy category B by the FDA. Animal studies have not revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy. Systemic administration of tetracycline has been associated with yellow-gray-brown discoloration of teeth in infants whose mothers took tetracycline in late pregnancy. Tetracycline topical is only recommended for use during pregnancy when benefits outweighs risk.
Tetracycline topical Breastfeeding Warnings
There are no data on the excretion of tetracycline topical into human milk. Systemic tetracycline is excreted into human milk in small amounts. Theoretical risks of dental staining and inhibition of bone growth exist, although unlikely. In one study, tetracycline levels were undetectable in nursing infants. Tetracycline is considered compatible with breast-feeding by the American Academy of Pediatrics.
See also
References for pregnancy information
- Cohlan SQ, Bevelander G, Tiamsic T (1963) "Growth inhibition of prematures receiving tetracycline." Am J Dis Child, 105, p. 453-61
- Kline AH, Blattner RJ, Lunin M (1964) "Transplacental effect of tetracyclines on teeth." JAMA, 188, p. 178-80
- (2002) "Product Information. Topicycline (tetracycline topical)." Roberts Pharmaceutical Corporation
References for breastfeeding information
- (1969) "Tetracycline in breast milk." Br Med J, 4, p. 791
- Roberts RJ, Blumer JL, Gorman RL, et al. (1989) "American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk." Pediatrics, 84, p. 924-36
- (2001) "Product Information. Achromycin (tetracycline)." Lederle Laboratories
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
